Prostate Cancer Screening: When Should Men Get Tested?

Medically Reviewed and Compiled by Dr. [Adam N. Khan], MD.

Prostate cancer is one of the most commonly diagnosed cancers among men, yet it can develop without noticeable symptoms during its early stages. This creates an important challenge: how can men identify potentially dangerous prostate cancer early without undergoing unnecessary tests or treatments?

The answer is not necessarily to screen everyone at the same age. Screening decisions depend on several factors, including age, family history, inherited genetic changes, overall health, life expectancy, and personal preferences.

Understanding the latest evidence behind prostate cancer screening guidelines can help men recognize when testing may be appropriate, what a prostate-specific antigen (PSA) result actually means, and when additional investigations might be necessary.

This guide explains screening recommendations, age-specific considerations, PSA testing, modern diagnostic approaches, and the potential benefits and disadvantages of early detection.

What Is Prostate Cancer Screening?

Prostate cancer screening involves testing men who do not have symptoms to identify possible signs of cancer before clinical problems develop.

The primary screening test is the prostate-specific antigen (PSA) blood test.

PSA is a protein produced by cells in the prostate gland. Small amounts normally enter the bloodstream, but elevated concentrations can sometimes indicate prostate abnormalities.

Importantly, an elevated PSA level does not automatically mean cancer.

Several noncancerous conditions can increase PSA, including:

  • Benign prostatic hyperplasia (BPH), which causes prostate enlargement.
  • Prostatitis, or inflammation of the prostate.
  • Urinary tract infections.
  • Recent urinary catheterization or certain prostate procedures.
  • Temporary fluctuations associated with ejaculation or other prostate-related factors.

Doctors interpret PSA results alongside age, previous PSA measurements, medical history, and other clinical findings.

Screening may identify cancer early enough to improve treatment opportunities. However, it can also identify slow-growing cancers that might never cause symptoms or shorten a person’s life.

That distinction is central to understanding screening recommendations.

Prostate Cancer Screening Guidelines: What Do Medical Organizations Recommend?

There is no universal recommendation that every man should undergo PSA testing annually.

Major medical organizations differ somewhat in their recommendations because they interpret the benefits and harms of screening differently.

Nevertheless, most contemporary guidance emphasizes informed, shared decision-making.

1. U.S. Preventive Services Task Force (USPSTF)

The USPSTF recommends an individualized approach to PSA-based screening.

Its final 2018 recommendation states:

  • Men aged 55–69: PSA screening should be an individual decision made after discussing potential benefits and harms with a healthcare professional.
  • Men aged 70 and older: The USPSTF recommends against routine PSA-based screening.

The recommendation recognizes that screening can reduce the risk of dying from prostate cancer in some men, but the absolute benefit is relatively small.

It also highlights potential harms, including false-positive results, unnecessary biopsies, overdiagnosis, and treatment complications.

Source: USPSTF – Prostate Cancer: Screening.

2. American Urological Association (AUA/SUO)

The American Urological Association and Society of Urologic Oncology recommend offering screening through shared decision-making.

Their 2023 early-detection guideline provides several important considerations:

  • A baseline PSA test may be offered between ages 45 and 50 for people at average risk.
  • Earlier screening, generally between ages 40 and 45, may be appropriate for individuals with increased risk.
  • Regular screening is recommended through shared decision-making for many men aged 50–69.
  • Screening intervals should be individualized rather than automatically repeated every year.

The guideline also emphasizes confirming a newly elevated PSA before proceeding to secondary biomarkers, imaging, or prostate biopsy.

Source: AUA/SUO – Early Detection of Prostate Cancer Guideline.

3. American Cancer Society (ACS)

The American Cancer Society recommends discussing the potential benefits and limitations of prostate cancer screening with a healthcare professional.

Its age-based discussion framework includes:

  • Age 50: Men at average risk who are expected to live at least another 10 years.
  • Age 45: Men at higher risk, including African American men and those with a first-degree relative diagnosed with prostate cancer before age 65.
  • Age 40: Men with more than one first-degree relative diagnosed at an early age.

These are ages to begin discussing screening, not automatic requirements to undergo testing.

Source: American Cancer Society – Prostate Cancer Early Detection.

Comparing the recommendations

Medical organizationMain screening approach
USPSTFIndividual decision at 55–69; against routine screening at 70+
AUA/SUOBaseline PSA may be offered at 45–50; earlier discussion for increased risk
American Cancer SocietyDiscussion at 50 for average risk, 45 for higher risk, and 40 for particularly high-risk family histories

These differences do not mean one organization necessarily considers screening beneficial and another considers it harmful. They reflect different approaches to balancing early detection against potential complications.

At What Age Should Men Start Prostate Cancer Screening?

Age is an important starting point, but it should never be the only factor.

A healthy 45-year-old man with a strong family history may benefit from an earlier discussion than a 60-year-old man with no significant risk factors.

Here is a practical overview.

Men younger than 40

Routine PSA screening is generally not recommended for average-risk men younger than 40.

However, individuals with unusually strong hereditary cancer histories or known pathogenic genetic variants may benefit from specialist counseling.

Men aged 40–49

This is an important period for men with increased risk.

Early screening discussions may be appropriate for:

  • Men with a father or brother diagnosed with prostate cancer at a relatively young age.
  • Men with multiple close relatives affected by prostate cancer.
  • African American men, who experience a disproportionate burden of prostate cancer.
  • Men with inherited BRCA2 or other relevant cancer-predisposition variants.

For average-risk men, routine testing during this period is not universally recommended.

Men aged 50–59

This is a common age range for beginning PSA screening discussions.

The decision should consider baseline PSA, family history, general health, and personal preferences.

A normal PSA result may support a longer interval before repeat testing.

Men aged 60–69

Screening decisions become particularly important during these years.

Some men may benefit from continued PSA testing, especially if their baseline PSA is elevated or they have additional risk factors.

Others may reasonably choose less frequent testing after discussing their previous results and overall health.

Men aged 70 and older

Routine screening is generally discouraged by the USPSTF because the likelihood of screening-related harms increases while the potential benefit often decreases.

However, clinical decisions should not be reduced to age alone. Individual circumstances, previous PSA values, health status, and symptoms still matter.

Who Is at Higher Risk of Prostate Cancer?

Not all men have the same likelihood of developing prostate cancer.

Understanding individual risk can help determine whether screening should begin earlier or occur more frequently.

1. Family history

A family history is one of the most important risk factors.

A man whose father or brother developed prostate cancer has a higher risk than someone without an affected first-degree relative.

Risk may be particularly elevated when:

  • Multiple relatives have been diagnosed.
  • Relatives developed cancer before age 60.
  • Several generations have experienced prostate, breast, ovarian, or pancreatic cancers.

These patterns may suggest an inherited cancer-predisposition syndrome.

2. Race and ancestry

Black men in the United States experience higher prostate cancer incidence and mortality than White men.

The reasons are complex and may involve inherited susceptibility, differences in access to healthcare, socioeconomic conditions, environmental exposures, and differences in diagnosis and treatment.

This disparity supports earlier conversations about screening rather than relying exclusively on average-risk recommendations.

3. Genetic mutations

Inherited changes in certain genes can increase prostate cancer risk.

Important examples include:

  • BRCA2.
  • BRCA1.
  • HOXB13.
  • ATM.
  • CHEK2.
  • Mismatch-repair genes associated with Lynch syndrome.

BRCA2 is particularly important because pathogenic variants are associated with increased risk of aggressive prostate cancer.

Men with relevant personal or family histories may benefit from genetic counseling and, when appropriate, genetic testing.

4. Age and overall health

Age remains one of the strongest established risk factors.

However, the decision to screen should also consider life expectancy.

A man with significant cardiovascular disease or another serious illness may be unlikely to benefit from detecting a slow-growing prostate cancer that would take many years to cause problems.

This is why screening decisions should consider the whole person rather than just a birth date.

PSA Testing: How Does It Work?

PSA testing is a straightforward blood test that measures prostate-specific antigen concentrations.

The result is usually reported in nanograms per milliliter (ng/mL).

Historically, a PSA concentration of 4 ng/mL was frequently used as a threshold for further investigation. However, modern clinical practice recognizes that no single PSA value reliably separates men with cancer from those without it.

Some men have prostate cancer despite PSA levels below 4 ng/mL, while many men with higher levels do not have cancer.

Doctors may consider:

  • Total PSA concentration.
  • Previous PSA measurements and changes over time.
  • Age and prostate volume.
  • Family history.
  • Relevant medications.
  • Recent infections or prostate inflammation.
  • Findings from clinical examinations.

What do different PSA levels mean?

The following table provides general context, not a diagnostic classification.

PSA levelGeneral interpretation
Below 2 ng/mLOften associated with lower risk, depending on age and individual circumstances
2–4 ng/mLMay warrant individualized interpretation
4–10 ng/mLOften requires further risk assessment
Above 10 ng/mLGreater concern and usually warrants prompt evaluation

A PSA result should never be interpreted in isolation.

For example, a PSA level of 5 ng/mL in a man with prostate enlargement and a recent urinary infection may have a different meaning from the same result in a man with a strong family history and no identifiable benign explanation.

Does an elevated PSA mean prostate cancer?

No.

An elevated result indicates that further evaluation may be appropriate, not that cancer has been confirmed.

Doctors may repeat the test after addressing temporary factors that could affect PSA.

Depending on the clinical picture, they may also recommend additional biomarkers, prostate MRI, or biopsy.

This stepwise approach can help reduce unnecessary invasive investigations.

What Happens If Your PSA Test Is Abnormal?

An abnormal PSA result can cause understandable anxiety. However, an elevated reading should be treated as a reason to investigate, not an immediate cancer diagnosis.

Modern prostate cancer evaluation generally follows a stepwise process.

Step 1: Repeat the PSA test

The AUA/SUO recommends repeating a newly elevated PSA before moving to secondary investigations.

PSA can fluctuate naturally, and temporary inflammation or infection may affect the result.

Repeating the test helps determine whether the elevation persists.

Step 2: Review additional risk factors

The healthcare professional may assess:

  • Age and family history.
  • Previous PSA results.
  • Prostate size.
  • Urinary symptoms.
  • Medication use.
  • History of prostate infections.
  • Genetic risk factors.

A digital rectal examination (DRE) may also be considered as part of the clinical assessment.

During this examination, a healthcare professional feels the prostate through the rectum to identify possible abnormalities.

A DRE cannot reliably exclude prostate cancer, and it is not a substitute for PSA testing.

Step 3: Consider additional blood or urine tests

Depending on the patient’s risk, clinicians may recommend additional tests, such as:

  • Free PSA percentage.
  • Prostate Health Index (PHI).
  • 4Kscore.
  • Other validated secondary biomarkers.

These tests can help estimate the probability of clinically significant prostate cancer and assist decisions about biopsy.

They are not definitive cancer tests.

Step 4: Multiparametric prostate MRI

Multiparametric MRI (mpMRI) has become an important part of modern prostate cancer assessment.

ESR Essentials: using the right scoring system in prostate MRI—practice recommendations by ESUR | European Radiology | Springer Nature Link

MRI can identify suspicious areas within the prostate and help clinicians decide whether a targeted biopsy is necessary.

The Prostate Imaging Reporting and Data System (PI-RADS) classifies MRI findings from 1 to 5:

  • PI-RADS 1: Very low likelihood of clinically significant cancer.
  • PI-RADS 2: Low likelihood.
  • PI-RADS 3: Intermediate or indeterminate likelihood.
  • PI-RADS 4: High likelihood.
  • PI-RADS 5: Very high likelihood.

MRI findings must be interpreted alongside PSA, prostate volume, clinical history, and other risk factors.

A reassuring MRI does not completely exclude clinically significant cancer.

Step 5: Prostate biopsy

A biopsy involves collecting small tissue samples from the prostate for examination under a microscope.

A pathologist can determine whether cancer is present and assess its grade.

The Gleason grading system and Grade Groups help describe how aggressive prostate cancer cells appear.

Grade Groups range from 1 to 5, with higher groups generally indicating more aggressive disease.

Biopsy is the method used to confirm a prostate cancer diagnosis, although the decision to perform it should be based on the overall clinical assessment.

Benefits and Risks of Prostate Cancer Screening

Screening has meaningful advantages, but it is not a risk-free preventive intervention.

Men should understand both sides before deciding whether to proceed.

Potential benefits

1. Earlier detection

Screening can identify prostate cancer before symptoms develop.

Some aggressive cancers are more treatable when detected before spreading beyond the prostate.

2. Better-informed treatment decisions

Earlier diagnosis can give patients and clinicians more time to evaluate treatment options.

Depending on the cancer’s characteristics, options may include active surveillance, surgery, radiation therapy, or other treatments.

3. Reduced risk of prostate cancer death

Randomized screening trials have demonstrated a modest reduction in prostate cancer mortality in some screened populations over long-term follow-up.

The European Randomized Study of Screening for Prostate Cancer (ERSPC) is an important example.

However, the benefit is not immediate, and it must be weighed against screening-related complications.

Potential risks

1. False-positive results

A false-positive PSA result occurs when PSA is elevated even though the individual does not have prostate cancer.

This can lead to repeated blood tests, additional imaging, anxiety, and potentially unnecessary biopsies.

2. Overdiagnosis

Overdiagnosis happens when screening identifies a prostate cancer that would never have caused symptoms or affected the person’s lifespan.

This is especially relevant because some prostate cancers grow very slowly.

3. Biopsy complications

Prostate biopsies can cause pain, bleeding, infection, and temporary urinary difficulties.

Severe infections are less common but can require urgent treatment.

4. Treatment-related complications

Some men diagnosed with prostate cancer undergo treatments that can affect their quality of life.

Potential complications include:

  • Erectile dysfunction.
  • Urinary incontinence.
  • Bowel irritation or changes.
  • Fertility and sexual health concerns.
  • Psychological distress.

These risks are among the reasons why active surveillance is appropriate for many men with low-risk prostate cancer.

Does Everyone With Prostate Cancer Need Treatment?

No. This is one of the most important distinctions in modern prostate cancer care.

Finding cancer does not automatically mean that immediate surgery or radiation is necessary.

Some prostate cancers grow slowly and may never become life-threatening.

For carefully selected men with low-risk localized disease, active surveillance may be recommended.

Active surveillance generally involves:

  • Periodic PSA testing.
  • Clinical assessments.
  • Repeat prostate MRI when appropriate.
  • Repeat biopsy according to the surveillance protocol.

The objective is to monitor the cancer and identify signs of progression while avoiding unnecessary treatment.

This approach differs from watchful waiting, which generally focuses on symptom management rather than attempting to detect disease progression early enough for curative treatment.

For additional context, readers can explore our guide on whether prostate cancer is curable.

Unique Clinical Takeaways

The most useful screening decisions often involve details that are overlooked when patients focus exclusively on their PSA numbers.

Here are five important considerations that deserve more attention.

1. Your baseline PSA may matter more than a single result

A single PSA measurement provides limited information.

Consider two men with a PSA of 3 ng/mL.

One has maintained a similar PSA level for several years. The other has experienced a substantial increase from a previously low baseline.

These situations may warrant different clinical evaluations.

However, PSA velocity should not be used alone to determine whether a biopsy is necessary. The broader clinical picture remains essential.

Actionable takeaway: Keep a record of previous PSA measurements and discuss changes over time rather than evaluating each result independently.

2. Genetic risk can be more informative than age alone

A man in his early forties with a BRCA2 pathogenic variant and a strong family history may deserve an earlier screening discussion than an average-risk man of the same age.

This is particularly important because inherited risk can influence not only the probability of developing prostate cancer but also the likelihood of developing clinically significant disease.

Family histories of breast, ovarian, pancreatic, and prostate cancer can provide useful clues.

Actionable takeaway: Prepare a three-generation family cancer history before discussing screening. Include the type of cancer and approximate age at diagnosis.

3. Urinary symptoms should not be confused with screening results

Frequent urination, weak urine flow, difficulty starting urination, and nighttime urination are common symptoms of benign prostate enlargement.

They do not automatically indicate prostate cancer.

Conversely, early prostate cancer frequently produces no noticeable urinary symptoms.

This creates two separate clinical questions:

  • Does the patient have symptoms requiring diagnostic evaluation?
  • Should an otherwise asymptomatic patient undergo screening?

These questions should not be treated as interchangeable.

Actionable takeaway: Do not delay medical evaluation because a PSA test is normal if you experience persistent urinary symptoms, blood in the urine, or other concerning changes.

4. Lifestyle factors deserve attention, but they cannot replace screening decisions

Obesity, metabolic health, physical inactivity, and dietary patterns are relevant areas of prostate cancer research.

Evidence linking individual lifestyle factors to aggressive prostate cancer is complex, and researchers continue investigating how metabolic and environmental exposures influence cancer development.

A healthy diet, regular physical activity, maintaining a healthy weight, and avoiding tobacco can support overall health.

However, no particular food, supplement, or exercise routine has been proven to eliminate prostate cancer risk.

Actionable takeaway: Treat lifestyle improvement as part of long-term health management, not as a replacement for risk assessment or appropriate screening.

5. The psychological consequences of screening deserve attention

An elevated PSA result can create substantial uncertainty.

Some men experience anxiety while waiting for repeat testing, MRI results, or biopsy findings. Others struggle with the possibility of a cancer diagnosis that might never become clinically significant.

This is sometimes described as the psychological burden of screening.

The impact may extend to partners and family members, particularly when decisions involve sexual function, fertility, or the possibility of major surgery.

Actionable takeaway: Ask your clinician what an abnormal result could mean before undergoing screening. Understanding the possible next steps can make the process less frightening and help prevent rushed decisions.

Emerging Advances in Prostate Cancer Screening and Early Detection

Prostate cancer assessment is moving beyond the traditional approach of relying on a single PSA threshold.

Several developments are helping clinicians better distinguish potentially aggressive cancers from low-risk abnormalities.

1. MRI-informed screening pathways

Multiparametric MRI is increasingly incorporated into diagnostic pathways for men with concerning PSA results.

MRI can help identify suspicious lesions, guide targeted biopsy, and potentially reduce unnecessary procedures.

Research continues to investigate how MRI could be incorporated earlier into screening pathways.

2. Risk calculators and personalized screening

Risk prediction tools combine information such as age, PSA, family history, previous biopsy findings, and other clinical variables.

These tools can help estimate the likelihood of clinically significant prostate cancer.

However, calculators are not diagnostic instruments and should not replace clinical judgment.

3. Genetic testing and precision medicine

Genetic testing can identify inherited variants associated with prostate cancer susceptibility.

For men with relevant family histories, this information may influence screening discussions and the need for genetic counseling.

Research is also exploring how tumor genetics can guide treatment once cancer has been diagnosed.

4. Improved biomarkers

Tests such as PHI and 4Kscore may help refine risk assessment when PSA results are uncertain.

Researchers are also investigating urine-based biomarkers and other molecular approaches.

Although promising, these technologies are not interchangeable with established screening recommendations, and their appropriate use depends on individual circumstances.

When Should You See a Doctor?

You should discuss prostate health with a healthcare professional if you have risk factors that may justify earlier screening.

Seek medical evaluation for symptoms such as:

  • Persistent difficulty urinating.
  • Weak or interrupted urine flow.
  • Frequent nighttime urination.
  • Blood in the urine or semen.
  • Persistent pelvic or lower-back discomfort.
  • Unexplained symptoms that concern you.

These symptoms are not specific to prostate cancer, but they deserve appropriate assessment.

New severe back pain accompanied by leg weakness, numbness around the groin, or loss of bladder or bowel control requires emergency medical evaluation.

For further reading, see our related articles:

Frequently Asked Questions

1. Is prostate cancer screening recommended for every man?

No. Screening is an individualized decision. Age, family history, genetic risk, overall health, and personal preferences should all influence the decision.

2. Is a PSA test enough to detect prostate cancer?

No. PSA testing helps estimate risk but cannot confirm or exclude cancer on its own. MRI, additional biomarkers, and biopsy may be needed.

3. How often should men get a PSA test?

There is no universal testing interval. Depending on baseline PSA and individual risk, clinicians may recommend repeat testing every two to four years or at another appropriate interval.

4. Can prostate cancer develop with a normal PSA?

Yes. Some prostate cancers occur in men with PSA levels considered normal. Persistent symptoms or concerning clinical findings should therefore receive appropriate evaluation.

5. Is prostate cancer screening painful?

The PSA blood test involves a routine blood draw and usually causes only brief discomfort. MRI is generally painless, while prostate biopsy may involve discomfort and temporary side effects.

6. Should men with a family history start screening earlier?

Often, yes. Men with an affected father or brother, particularly when diagnosed at a younger age, should discuss earlier screening. Genetic counseling may also be appropriate.

7. Can an enlarged prostate increase PSA?

Yes. Benign prostatic hyperplasia can increase PSA without cancer being present. This is one reason clinicians consider prostate size and other clinical factors when interpreting results.

References and Citations

The following authoritative medical sources support the screening recommendations, diagnostic information, and clinical discussion in this article.

1. U.S. Preventive Services Task Force (USPSTF). Prostate Cancer: Screening. Final Recommendation Statement, 2018.
Read the USPSTF recommendation.

2. American Urological Association (AUA) and Society of Urologic Oncology (SUO). Early Detection of Prostate Cancer Guideline, 2023.
Read the AUA/SUO guideline.

3. American Cancer Society (ACS). Prostate Cancer Early Detection, Testing and Screening Recommendations.
Read the ACS screening guidance.

4. National Cancer Institute (NCI). Prostate Cancer Screening (PDQ): Health Professional Version.
Read the NCI evidence review.

5. European Randomized Study of Screening for Prostate Cancer (ERSPC). Long-term evidence concerning PSA-based prostate cancer screening and mortality reduction.
Explore ERSPC research through PubMed.

6. National Comprehensive Cancer Network (NCCN). Prostate Cancer Early Detection Clinical Practice Guidelines.
Explore NCCN clinical guidelines.

7. European Association of Urology (EAU). Guidelines on Prostate Cancer.
Read the EAU prostate cancer guidelines.

Clinical currency note: These are identifiable guideline and research resources, not a claim that every recommendation has been newly revised in 2026. Before publication, verify the latest available editions and any updated recommendations, particularly for NCCN and EAU.

Medical Disclaimer

This article is intended for educational and informational purposes only. It does not replace professional medical advice, diagnosis, or treatment. Prostate cancer screening decisions should be made in consultation with a qualified healthcare professional who can evaluate individual risk factors, medical history, and personal preferences. Do not delay seeking medical attention because of information presented in this article.